"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 7 | 2 | 9 |
| 1997 | 17 | 2 | 19 |
| 1998 | 17 | 2 | 19 |
| 1999 | 11 | 2 | 13 |
| 2000 | 15 | 6 | 21 |
| 2001 | 9 | 5 | 14 |
| 2002 | 15 | 4 | 19 |
| 2003 | 20 | 5 | 25 |
| 2004 | 15 | 12 | 27 |
| 2005 | 29 | 9 | 38 |
| 2006 | 14 | 18 | 32 |
| 2007 | 18 | 22 | 40 |
| 2008 | 32 | 12 | 44 |
| 2009 | 22 | 22 | 44 |
| 2010 | 32 | 17 | 49 |
| 2011 | 40 | 19 | 59 |
| 2012 | 36 | 19 | 55 |
| 2013 | 44 | 28 | 72 |
| 2014 | 40 | 17 | 57 |
| 2015 | 58 | 34 | 92 |
| 2016 | 67 | 29 | 96 |
| 2017 | 47 | 19 | 66 |
| 2018 | 53 | 24 | 77 |
| 2019 | 46 | 20 | 66 |
| 2020 | 46 | 7 | 53 |
| 2021 | 56 | 16 | 72 |
| 2022 | 22 | 1 | 23 |
| 2023 | 25 | 2 | 27 |
| 2024 | 9 | 19 | 28 |
| 2025 | 26 | 6 | 32 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Synthesis, Structure-Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein-Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. J Med Chem. 2025 Sep 25; 68(18):19396-19414.
-
Tackling the Cardio-Kidney-Metabolic Burden in Cancer. Curr Atheroscler Rep. 2025 Sep 15; 27(1):92.
-
Comparison of the Cytotoxicity, Internalization and Anti-Cancer Drug Delivery Efficacy of Nature Killer Cell Derived Nanovesicles and Extracellular Vesicles. Int J Nanomedicine. 2025; 20:10683-10700.
-
Blinatumomab use in pediatric B-ALL: where are we now? Blood Adv. 2025 Aug 12; 9(15):3946-3954.
-
Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group. Clin J Oncol Nurs. 2025 Aug 04; 29(4):303-312.
-
New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2025 Oct; 72(10):e31917.
-
Simultaneous Presentation of Cutaneous Waldenstr?m Macroglobulinemia and Acalabrutinib-Related Toxicity. Am J Dermatopathol. 2025 Oct 01; 47(10):786-789.
-
Caregiving for Children With Acute Lymphoblastic Leukemia Receiving Home-Based Blinatumomab: Caregiver Experiences and Recommendations. Pediatr Blood Cancer. 2025 Oct; 72(10):e31913.
-
The long-term effects of chemotherapy on normal blood cells. Nat Genet. 2025 Jul; 57(7):1684-1694.